Read more about biosimilars breaking policy and perceptual barriers.
Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.
Biosimilars medicines, (the approved follow-on products to innovator biologics) which have come off-patent, present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems.
But biosimilars aren’t like standard generic medicines and cannot be easily replicated. The extent to which they will win market share will depend on a range of factors including regulatory behaviour, physician and patient attitudes, trust and understanding, as well as manufacturing capabilities. Research Partnership has been working with both biologic and biosimilar manufacturers and understands the market factors at play.
We can help you with:
Opportunity and demand assessment
Understanding the global and local market opportunity
Segmenting the market
Product and portfolio development
Brand positioning, launch and beyond